New insights into cancer progression and immune evasion have emerged, including discoveries of innate immune checkpoint inhibitors showing efficacy against solid tumors in preclinical models and studies identifying metabolic and inflammatory signaling axes driving ovarian and breast cancer resistance and metastasis. These findings offer promising therapeutic targets and strategies to overcome tumor heterogeneity and immunosuppressive microenvironments, potentially enhancing immunotherapy responses across multiple cancer types.